Chromadex Profit Margin

As of the most recent data (June 2026), CDXC shows a profit margin of 53.69%. That compares with 27.68% in the prior-year period — up 93.9% year over year. That is above the Healthcare sector average of 14.34%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CDXC's profit margin is now 53.69% (was 27.68%) — a 93.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Chromadex is outperforming or lagging.

The Healthcare sector average profit margin is about 14.34%. Chromadex is at 53.69%, which is higher that average. That is roughly 274.3% above the sector mean. Use the comparison chart on this page to see how CDXC stacks up against individual peers as well.

That compares with 27.68% in the prior-year period — up 93.9% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Chromadex with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Chromadex's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 53.69%) with ownership activity and broader fundamentals.